证券日报网讯 1月8日，金达威发布公告称，公司于2026年1月8日召开第九届董事会第十次会议，审议 通过《关于增加募投项目实施主体并开立募集资金专户的议案》，同意增加公司全资子公司内蒙古金达 威药业有限公司、厦门金达威维生素有限公司、厦门金达威生物科技有限公司、厦门金达威电子商务有 限公司、金达威控股有限公司作为公司募集资金投资项目"信息化系统建设项目"的实施主体，并增加上 述子公司的注册地址作为募投项目实施地点。同意相关子公司开立募集资金专户，用于募集资金的存 放、管理和使用。 （文章来源：证券日报） ...

Summary of Key Points Core Viewpoint The report outlines the fundraising and usage status of Aimer Group for the first half of 2025, detailing the total amount raised, its allocation to projects, and the management of these funds. Group 1: Fundraising Overview - The total net amount raised from the initial public offering (IPO) was RMB 761.25 million after deducting issuance costs of RMB 78.56 million, with all funds received by May 20, 2021 [1][2]. - As of December 31, 2024, a total of RMB 619.01 million had been directly invested in fundraising projects, with a remaining balance of RMB 43.75 million in the fundraising account [2][4]. Group 2: Fund Usage and Management - By June 30, 2025, the cumulative investment in fundraising projects reached RMB 640.34 million, with RMB 128.73 million from completed projects permanently supplementing working capital [2][5]. - The company has established a management system for fundraising, including a three-party supervision agreement with banks and sponsors to ensure the safety of fund usage [3][4]. Group 3: Project Adjustments and Financial Management - The company has adjusted the use of previously allocated funds, redirecting RMB 162.51 million from the "Vietnam Production Base" project to the "Brand Promotion" project due to changes in market conditions [7][12]. - The "Brand Promotion" project has incurred expenditures of RMB 146.44 million as of June 30, 2025, with the completion date extended to December 2025 [8][10]. Group 4: Compliance and Reporting - The company confirms that all disclosures regarding the use of fundraising comply with relevant laws and regulations, with no significant violations reported [6][9].